My wife (who's also a physician): He just had the blood test done by his primary care physician that was consistent with him being at a greater risk for Alzheimer's.
Me: Really? I didn't know the blood test had been given final approval by the FDA.
The FDA granted a breakthrough device designation for the blood test last year, but I wasn't aware of the final approval.
The Lumipulse G pTau 217/B-Amyloid 1-42 plasma ratio blood test was approved on 5/16/2025, 16 days after I retired.
It's a biomarker that detects an increased risk for the amyloid plaques that have been associated with Alzheimer's disease.
I basically haven't read any of my medical journals or updates since retiring.
But this reminded me that I don’t like being uninformed, especially in an area of medicine (evaluating patients for possible dementia) that was a significant part of my career.
My schedule has been pretty packed lately 😏, but I'm sure I can carve out a bit of time each day for some medical literature reviews.
No comments:
Post a Comment